Analyst Ratings For NASDAQ:EPZM – Epizyme (NASDAQ:EPZM)

.

Some recent analyst ratings include

• 4/24/2018-SunTrust Banks Reiterated Rating of Buy.
• 2/1/2018-Roth Capital initiated coverage with a Buy rating.
• 1/24/2018-Jefferies Group Reiterated Rating of Buy .
• 1/10/2018-Morgan Stanley initiated coverage with a Overweight rating.

Recent Insider Trading Activity For NASDAQ:EPZM – Epizyme (NASDAQ:EPZM)
NASDAQ:EPZM – Epizyme (NASDAQ:EPZM) has insider ownership of 21.50% and institutional ownership of 85.77%.

• On 2/5/2018 Matthew Ros, COO, sold 72,264 with an average share price of $16.63 per share and the total transaction amounting to $1,201,750.32.
• On 10/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $16.44 per share and the total transaction amounting to $246,600.00.
• On 9/25/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $16.81 per share and the total transaction amounting to $252,150.00.
• On 9/18/2017 David M Mott, Director, bought 200,000 with an average share price of $15.25 per share and the total transaction amounting to $3,050,000.00.
• On 8/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $15.68 per share and the total transaction amounting to $235,200.00.
• On 7/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $13.44 per share and the total transaction amounting to $201,600.00.
• On 6/30/2017 Andrew E Singer, CFO, sold 3,024 with an average share price of $15.50 per share and the total transaction amounting to $46,872.00.

Recent Trading Activity for NASDAQ:EPZM – Epizyme (NASDAQ:EPZM)
Shares of NASDAQ:EPZM – Epizyme closed the previous trading session at 13.25 down -2.05 13.40% with shares trading hands.